Filing Details
- Accession Number:
- 0001209191-20-009865
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2020-02-18 07:05:28
- Reporting Period:
- 2020-01-08
- Accepted Time:
- 2020-02-18 07:05:28
- Original Submission Date:
- 2020-01-10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1478320 | Adaptive Biotechnologies Corp | ADPT | Biological Products, (No Disgnostic Substances) (2836) | 270907024 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1799081 | L Stacy Taylor | C/O Adaptive Biotechnologies 1551 Eastlake Ave E Ste 200 Seattle WA 98102 | Svp And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-01-08 | 662 | $6.55 | 1,962 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-01-08 | 662 | $30.00 | 1,300 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-01-08 | 662 | $0.00 | 52,662 | $6.55 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
52,000 | 2028-04-24 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.
- The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.